AJTMH HINARI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 13(6), 1964, pp. 803-810
Copyright © 1964 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zaki, M. H.
Right arrow Articles by De Ramos, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zaki, M. H.
Right arrow Articles by De Ramos, S.

Astiban® in Schistosomiasis Mansoni: A Controlled Therapeutic Trial in a Nonendemic Area*

Mahfouz H. Zaki{dagger}, Howard B. Shookhoff{ddagger}, Max Sterman§ AND Stanley De Ramos||
Columbia School of Public Health and Administrative Medicine, and the New York City Health Department

One hundred and thirty-five patients suffering from schistosomiasis mansoni were divided into two groups at random. An experimental group of 69 patients was treated with a 20-ml course of a 10 percent solution of antimony dimercaptosodium succinate (TWSb/6 or Astiban®) over a 4- to 5-day period, while a control group of 66 patients was treated with an 80-ml course of 6.3 percent solution of antimony pyrocatechol sodium sulphonate (stibophen or Fuadin®) administered over a 6- to 7-week period.

The two drugs were moderately tolerated. Vomiting and rashes and/or pruritus were frequently encountered in the Astiban group while joint pains were a prominent feature during Fuadin therapy.

The cure rates obtained after a follow-up period of at least four months involving six stool examinations were 79.6 percent and 80.4 percent in the Astiban and Fuadin groups, respectively.

Under the existing conditions in New York City, Astiban has proved to be a potent schistosomicidal drug which can be applied with a reasonable degree of safety on an outpatient basis in mass therapy.


* Presented at the Eleventh Annual Meeting of the American Society of Tropical Medicine and Hygiene, Atlanta, Georgia, November 1962.


{dagger} Assistant Professor, Department of Environmental Medicine and Community Health, State University of New York, N. Y.


{ddagger} Chief, Tropical Disease Division, New York City Health Department.


§ Physician in Charge, Washington Heights Tropical Disease Clinic, New York City.


|| Public Health Physician (Epidemiologist), New York City Health Department.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1964 by the American Society of Tropical Medicine and Hygiene.